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Abstract
Background: Observational studies have shown that serum magnesium levels are inversely associated with risk of
cardiovascular disease, but whether this association is causal is unknown. We conducted a Mendelian randomisation
study to investigate whether serum magnesium levels may be causally associated with coronary artery disease (CAD).
Methods: This Mendelian randomisation analysis is based on summary-level data from the CARDIoGRAMplusC4D
consortium’s 1000 Genomes-based genome-wide association meta-analysis of 48 studies with a total of 60,801 CAD cases
and 123,504 non-cases. Six single-nucleotide polymorphisms associated with serum magnesium levels at genome-wide
significance were used as instrumental variables.
Results: A genetic predisposition to higher serum magnesium levels was inversely associated with CAD. In conventional
Mendelian randomisation analysis, the odds ratio of CAD was 0.88 (95% confidence interval [CI] 0.78 to 0.99; P = 0.03) per
0.1-mmol/L (about 1 standard deviation) increase in genetically predicted serum magnesium levels. Results were
consistent in sensitivity analyses using the weighted median and heterogeneity-penalised model averaging methods,
with odds ratios of 0.84 (95% CI 0.72 to 0.98; P = 0.03) and 0.83 (95% CI 0.71 to 0.96; P = 0.02), respectively.
Conclusions: This study based on genetics provides evidence that serum magnesium levels are inversely associated with
risk of CAD. Randomised controlled trials elucidating whether magnesium supplementation lowers the risk of CAD,
preferably in a setting at higher risk of hypomagnesaemia, are warranted.
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Background
Magnesium is the second most abundant intracellular
cation. It plays a crucial role in many processes regulat-
ing cardiovascular function, such as vascular tone, endo-
thelial function and myocardial excitability, and it is
involved in regulation of glucose and insulin metabolism
[1, 2]. Experimental evidence indicates that magnesium in-
sufficiency promotes atherosclerosis and that magnesium
fortification attenuates atherogenesis [2–7]. Moreover,
randomised controlled trials have shown that magnesium
supplementation improves endothelial function [8, 9] and
reduces blood pressure [8, 10–12], arterial stiffness [13],
fasting glucose [12, 14], insulin resistance [15] and
postoperative arrhythmias [16, 17]. Randomised controlled
trials assessing whether magnesium supplementation may
prevent cardiovascular events are lacking.
Evidence from observational studies indicates that high
circulating magnesium levels and magnesium intake are
associated with a modest reduction in risk of cardiovascu-
lar disease, including coronary heart disease [18, 19], but
the causality of these associations is unknown. The ob-
served inverse association between magnesium and car-
diovascular disease may be due to confounding by other
potentially cardioprotective nutrients in magnesium-rich
foods or by health behaviours adopted by individuals
consuming these foods. Rich food sources of magnesium
include green leafy vegetables, legumes, nuts, seeds, avo-
cados, dark chocolate, whole grains, yoghurt and fish. It
has been estimated that magnesium intake from a normal
Western diet is often inadequate. In the USA, two-thirds
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of the adult population has a magnesium intake below the
estimated average requirement [20].
Exploiting genetic variants as instrumental variables of
an exposure can strengthen causal inference regarding
an exposure-outcome relationship. This technique,
known as Mendelian randomisation (MR), reduces
confounding because genetic variants are randomly
allocated at meiosis and thus should be unrelated to
self-selected lifestyle factors and behaviours. It also over-
comes reverse causation bias since allelic randomisation
always precedes the onset of disease. Causal inference
from an MR study relies on the instrumental variable
assumptions, which require that the genetic variant is
robustly associated with the exposure; independent of
confounders of the exposure-outcome relationship; and
influences the outcome through the exposure only and
not through any alternative causal pathway (Fig. 1) [21].
We applied a two-sample MR framework to determine
the causal association between serum magnesium levels
and coronary artery disease (CAD).
Methods
Genetic variants and data sources
We used an MR study design based on publicly available
summary-level data from genome-wide association
studies (GWASs) (Table 1). As instrumental variables for
the MR analyses, we selected all single-nucleotide poly-
morphisms (SNPs) associated with serum magnesium
levels at genome-wide significance (P < 5×10− 8) in the
largest available GWAS on serum magnesium levels
[22]. We selected all six SNPs that achieved genome-
wide significance in the joint analysis of the discovery
(n = 15,366 individuals) and replication (n = 8463 indi-
viduals) cohorts [22]. All the SNPs were in different
genomic regions and in linkage equilibrium.
Summary-level data (beta coefficients and standard
errors) for the associations of the six magnesium-associated
SNPs with CAD were acquired from the CARDIoGRAM-
plusC4D consortium’s 1000 Genomes-based genome-wide
association meta-analysis of 60,801 CAD cases and 123,504
non-cases from 48 studies [23]. One SNP (rs7965584) was
not part of the CARDIoGRAMplusC4D dataset and was
replaced by a linked SNP (rs10858938; r2 = 0.96 in
Europeans). In the CARDIoGRAMplusC4D consortium,
CAD was defined using a broad definition that included
myocardial infarction (about 70% of the total number of
cases), acute coronary syndrome, chronic stable angina or
coronary artery stenosis of at least 50% [23]. Ethical
approval was not sought, because this study involved
analysis of publicly available summary-level data (beta
coefficients and standard errors) from GWASs, and no
individual-level data were used.
Statistical analysis
The main analysis was conducted using the conventional
inverse-variance weighted method [24] (hereafter referred
to as conventional MR analysis). Several sensitivity ana-
lyses were carried out, including (1) the leave-one-out
analysis, in which one SNP in turn was removed to evalu-
ate the impact of outlying SNPs; (2) the weighted median
method, which gives accurate estimates if at least 50% of
the instrumental variables are valid [24]; (3) the
heterogeneity-penalised model averaging method, which
provides consistent estimates if a plurality of the instru-
mental variables are valid [25]; and (4) MR-Egger regres-
sion, which can detect and adjust for pleiotropy [24, 26].
MR-Egger is disposed to effect estimate dilution due to
the NO Measurement Error (NOME) assumption for the
instrument-exposure associations. The NOME assump-
tion was tested using the I2GX statistic, and the MR-Egger
estimate was adjusted for dilution using the simula-
tion extrapolation (SIMEX) method [27]. The strength
of the instrumental variables was assessed using the
F-statistic [28].
To investigate potential pleiotropy and mediating path-
ways from serum magnesium to CAD, we performed con-
ventional MR analyses of the association of serum
magnesium levels with cardiometabolic risk factors, using
publicly available GWAS data [29–34] (Table 1).
All reported odds ratios (ORs) with their 95% confidence
intervals (CIs) are scaled to a 0.1-mmol/L (about one stand-
ard deviation [SD]) increase in serum magnesium levels.
All statistical tests were two-sided and considered statisti-
cally significant at P < 0.05. The analyses were conducted
using the mrrobust [35] and MendelianRandomization
[36] packages.
Results
The six magnesium-associated SNPs explained 1.62% of
the variance in serum magnesium levels, and the mean
F-statistic was 64 (Table 2). Five of the SNPs were
Fig. 1 Diagram of the instrumental variables assumptions for Mendelian
randomisation. The three assumptions are: (1) the genetic variant must
be robustly associated with the exposure; (2) the genetic variant
should not be associated with confounders of the exposure-outcome
association; and (3) the genetic variant must influence the outcome
through the exposure only and not through any direct or alternative
pathways. The dashed lines represent pathways that violate the
assumptions. CAD coronary artery disease
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inversely, albeit non-statistically significantly, associated
with CAD (Table 2). In conventional MR analysis, genetic-
ally predicted serum magnesium was inversely associated
with CAD, but there was evidence of heterogeneity be-
tween estimates from individual SNPs (Pheterogeneity = 0.06).
The ORs of CAD per a 0.1-mmol/L (about one SD) in-
crease in genetically predicted serum magnesium levels
were 0.88 (95% CI, 0.78–0.99; P = 0.03) and 0.88 (95% CI,
0.74–1.05; P = 0.14) when standard errors were calculated
using fixed-effects and random-effects models, respectively
(Fig. 2). In the leave-one-out analysis, it was found that
rs11144134 in the TRPM6 gene region was responsible for
the heterogeneity among estimates from individual SNPs.
After exclusion of this SNP, there was no heterogeneity
between estimates (Pheterogeneity = 0.73), and the OR was
0.82 (95% CI, 0.72–0.93; P = 0.002) in both fixed-effects
and random-effects models (Fig. 2).
Results were consistent in sensitivity analyses using the
weighted median (OR, 0.84; 95% CI, 0.72–0.98; P = 0.03)
and heterogeneity-penalised model averaging (OR, 0.83;
95% CI, 0.71–0.96; P = 0.02) methods (Additional file 1:
Table S1). The MR-Egger analysis did not provide
evidence of either directional pleiotropy (intercept –0.023;
P = 0.21) or a causal association (OR = 1.19; 95% CI,
0.72–1.98; P = 0.50), but the precision of the estimates
was low (Additional file 1: Table S1). I2GX was 0.87
(relative bias of 13% towards the null), and adjusting
for dilution bias using the SIMEX method did not
materially change the MR-Egger estimate (Additional file 1:
Table S1).
Table 1 Details of studies and datasets used for analyses
Exposure/outcome Consortium Participants Web source if publicly available
Serum magnesium CHARGE and replication studies [22] 23,829 individuals of European
ancestry
Not available
Coronary artery disease CARDIoGRAMplusC4D consortium’s
1000 Genomes-based GWAS [23]
184,305 individuals (60,801 CAD
cases and 123,504 non-cases) of mainly
European (77%) and Asian (19%) ancestry
www.cardiogramplusc4d.org/
Blood pressure ICBP [29] 69,395 individuals of European ancestry www.ncbi.nlm.nih.gov/projects/
gap/cgi-bin/study.cgi?study_
id=phs000585.v1.p1
Lipids GLGC [30] 188,577 individuals of European ancestry csg.sph.umich.edu/abecasis/
public/lipids2013/
Glycaemic traits MAGIC [31] 46,186 non-diabetic individuals of
European ancestry
www.magicinvestigators.org/
Body mass index GIANT [32] 339,224 individuals of mainly European
(95%) ancestry
portals.broadinstitute.org/collaboration/
giant/index.php/GIANT_consortium
Waist-to-hip ratio GIANT [33] 224,459 individuals of mainly European
(94%) ancestry
portals.broadinstitute.org/collaboration/
giant/index.php/GIANT_consortium
Smoking TAGC [34] 74,053 individuals of European ancestry www.med.unc.edu/pgc/results-and-
downloads
CHARGE Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium, GIANT Genetic Investigation of Anthropometric Traits, GLGC Global Lipids
Genetics Consortium, ICBP International Consortium for Blood Pressure, MAGIC Meta-Analyses of Glucose and Insulin-related traits Consortium, TAGC Tobacco and
Genetics Consortium
Table 2 Characteristics of the single-nucleotide polymorphisms associated with serum magnesium levels
Association with magnesiuma Association with CADa
SNP Closest gene Chr EAb EAFc % variance explained F-statistic Beta (mmol/L) SE P Betad SE P
rs4072037 MUC1 1 T 0.54 0.57 136 0.010 0.001 2.0 × 10−36 −0.015 0.010 0.11
rs7965584e ATP2B1 12 A 0.71 0.25 60 0.007 0.001 1.1 × 10−16 −0.016 0.011 0.13
rs3925584 DCDC5 11 T 0.55 0.25 60 0.006 0.001 5.2 × 10−16 −0.016 0.010 0.09
rs11144134 TRPM6 9 C 0.08 0.23 55 0.011 0.001 8.2 × 10−15 0.039 0.019 0.04
rs13146355 SHROOM3 4 A 0.44 0.19 45 0.005 0.001 6.3 × 10−13 −0.003 0.010 0.76
rs448378 MDS1 3 A 0.53 0.13 30 0.004 0.001 1.3 × 10−8 −0.017 0.009 0.06
CAD coronary artery disease, Chr chromosome, EA effect allele, EAF effect allele frequency, SE standard error, SNP single-nucleotide polymorphism
aBeta coefficients and standard errors were obtained from genome-wide association studies on serum magnesium (23,829 individuals) [22] and CAD (60,801 cases
and 123,504 non-cases) [23]
bAllele associated with higher serum magnesium levels
cFrequency of the magnesium-raising allele in the magnesium genome-wide association study [22]
dLog odds ratio of CAD for each additional magnesium-increasing allele
eProxy (rs10858938; r2 = 0.96 in European descent individuals) was used in the CAD data
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In conventional MR analyses, genetic predisposition to
higher serum magnesium levels was weakly associated
with higher systolic blood pressure (P = 0.04) and triglyc-
erides (P = 0.04), but was not associated with diastolic
blood pressure, cholesterol, fasting glucose, fasting insu-
lin, insulin resistance, body mass index, waist-to-hip ra-
tio or smoking (Table 3).
Discussion
The main result of this study is that genetic variants predis-
posing to higher serum magnesium levels may confer a de-
creased risk of CAD. A genetically predicted 0.1-mmol/L
(about one SD) increase in serum magnesium levels was
associated with 12% lower odds of CAD in the primary
analysis. This finding corroborates the results from obser-
vational prospective studies showing inverse associations of
circulating magnesium levels and dietary magnesium intake
with risk of coronary heart disease and cardiovascular dis-
ease [18] (Fig. 3).
There is no gold standard MR analysis method. Avail-
able methods have advantages and limitations that balance
precision and adjustment for bias. In the present study,
several MR approaches were applied to evaluate the ro-
bustness of the causal association between serum magne-
sium levels and CAD. Although we cannot entirely rule
out pleiotropy, we observed a consistent inverse associ-
ation between serum magnesium levels and CAD in con-
ventional MR analysis and sensitivity analyses using the
weighted median and heterogeneity-penalised model aver-
aging methods. MR-Egger analysis, which has lower statis-
tical power compared with the other methods, suggested
no bias due to pleiotropy (i.e. when a genetic variant
affects more than one phenotype) and did not detect a
causal association, but the confidence interval was wide.
The I2GX and F-statistics were high, suggesting that
violation of the NOME assumption was limited and that
weak instrument bias due to dilution did not materially
affect the results. As in any MR study, we cannot entirely
rs4072037
rs7965584a
rs3925584
rs11144134
rs13146355
rs448378
Overall, fixed−effects
Overall, random−effects
Overall, excluding SNP in TRPM6
MUC1
ATP2B1
DCDC5
TRPM6
SHROOM3
MDS1
0.86 (0.71−1.04)
0.79 (0.58−1.08)
0.76 (0.56−1.04)
1.42 (1.01−2.00)
0.94 (0.64−1.38)
0.65 (0.41−1.03)
0.88 (0.78−0.99)
0.88 (0.74−1.05)
0.82 (0.72−0.93)
 0.11
 0.13
 0.09
 0.04
 0.76
 0.06
 0.03
 0.14
 0.002
Closest geneSNP OR (95% CI) P
10.4 0.6 0.8 1.4 2
Odds ratio of CAD per 0.1 mmol/L increase in serum magnesium levels
Fig. 2 Association between genetically predicted serum magnesium levels and coronary artery disease. Odds ratios are scaled to a genetically
predicted 0.1-mmol/L (about one SD) increase in serum magnesium levels. Analysis was conducted using inverse-variance weighted meta-analysis with
standard errors calculated using fixed-effects or random-effects weights. Pheterogeneity between estimates from individual SNPs was 0.06 in analysis
including all six SNPs and 0.74 in analysis excluding the outlying SNP in the TRPM6 gene. aProxy (rs10858938) was used in the coronary artery disease
data. CAD coronary artery disease, CI confidence interval, OR odds ratio
Table 3 Associations between genetically predicted serum
magnesium levels and cardiometabolic risk factors
Outcome Estimatea P value
Continuous outcomes Beta (95% CI)
Diastolic blood pressure 0.46 (−0.34 to 1.26) mm Hg 0.26
Systolic blood pressure 1.31 (0.05 to 2.57) mm Hg 0.04
Low-density lipoprotein
cholesterol
0.06 (−0.00 to 0.13) SD 0.07
High-density lipoprotein
cholesterol
−0.03 (−0.09 to 0.03) SD 0.34
Triglycerides 0.06 (0.00 to 0.12) SD 0.04
Fasting glucose 0.02 (−0.03 to 0.07) mmol/L 0.35
Fasting insulin 0.02 (−0.03 to 0.07) log pmol/L 0.43
HOMA-IR 0.01 (−0.04 to 0.06) 0.67
BMI −0.02 (−0.07 to 0.02) SD 0.34
Waist-to-hip ratio adjusted
for BMI
0.02 (−0.03 to 0.07) SD 0.50
Cigarettes per day −0.59 (−1.66 to 0.49)
cigarettes/day
0.29
Binary outcomes OR (95% CI)
Ever smoker 1.00 (0.98 to 1.01) 0.62
Former smoker 1.00 (0.98 to 1.02) 0.78
BMI body mass index, CI confidence interval, HOMA-IR homeostatic model
assessment of insulin resistance, OR odds ratio, SD standard deviation
aEstimates correspond to a 0.1-mmol/L (about one SD) increase in genetically
predicted serum magnesium levels
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exclude population stratification as a source of bias in this
study. However, the GWAS datasets used for the present
analyses largely comprised individuals of European
ancestry and adjustment was made for ancestry within the
contributing studies, reducing possible bias due to
population stratification.
There are several plausible mechanisms whereby magne-
sium may affect the risk of CAD. Magnesium is involved
in blood pressure regulation and in glucose and insulin
metabolism [1, 2]. Meta-analyses of randomised controlled
trials have shown that magnesium supplementation may
modestly reduce blood pressure [8, 10–12], fasting glucose
[12, 14] and insulin resistance [15]. However, we found no
evidence that genetically higher magnesium levels were
associated with lower blood pressure or glycaemic traits,
suggesting that these risk factors are not likely mediators
or confounders of the magnesium-CAD relationship. In
addition, the inverse association between serum magne-
sium levels and CAD is unlikely explained by major lipids,
as genetically higher magnesium levels were not associated
with cholesterol but were weakly associated with higher
triglycerides, which increase CAD risk [37].
Magnesium could potentially confer protection against
CAD by enhancing endothelium-dependent vasodilation
and reducing vascular resistance, oxidative stress and
oxidised lipids, inflammation and thrombosis, and by
anti-arrhythmic effects [2, 4, 7, 16, 17]. Several [8, 9, 13]
but not all [38, 39] randomised trials have shown that
magnesium supplementation improves endothelial func-
tion and reduces arterial stiffness. The inconsistent re-
sults may be related to magnesium status among study
participants, as improvement in endothelial function
with magnesium supplementation was observed in trials
involving patients with low serum magnesium levels [9]
and patients using diuretics [8], which often cause hypo-
magnesaemia. Both extracellular and intracellular free
magnesium can modulate vascular smooth muscle tone
[2]. Extracellular magnesium is considered to be a
calcium antagonist, because it inhibits many of the
physiological actions of calcium [2, 40]. Magnesium de-
creases calcium release from and into the sarcoplasmic
reticulum and protects the cells against calcium overload
during myocardial ischaemia [2, 40]. Multiple lines of
evidence indicate that a modestly elevated serum cal-
cium level increases CAD risk [41–43]. In this context,
mutations in TRPM6 (encoding a transient receptor po-
tential cation channel) cause hypomagnesaemia with
secondary hypocalcaemia [44, 45]. Hence, the observed
positive association between the magnesium-raising
allele of the genetic variant in TRPM6 and CAD might
be mediated by calcium. Another magnesium-associated
genetic variant is located nearby the ATP2B1 gene,
which encodes plasma-membrane calcium ATPase re-
sponsible for removal of calcium ions from cells [22].
A limitation of this study is that the specific biological
functions of most of the genetic variants associated with
serum magnesium levels are unknown (Additional file 1:
Table S2). However, the magnesium-associated SNPs
have shown association with hypomagnesaemia and with
phenotypes related to serum magnesium levels, such as
fasting glucose (SNP in MUC1), bone mineral density
(SNPs in MUC1 and TRPM6) and kidney function
(SNPs in SHROOM3 and DCDC5) [22]. Kidney function
has been associated with cardiovascular disease risk in
CAD
CHD
CVD
CHD
CVD
 Serum magnesium per 0.1 mmol/L
 Serum magnesium per 0.1 mmol/L
 Serum magnesium per 0.1 mmol/L
 Dietary magnesium per 200 mg/day
 Dietary magnesium per 200 mg/day
0.88 (0.78−0.99)
0.91 (0.81−1.02)
0.84 (0.75−0.94)
0.78 (0.67−0.92)
0.89 (0.75−1.05)
 Current study
 18
 18
 18
 18
Outcome Exposure OR/RR (95% CI) Reference
10.65 0.8 1.1
Odds ratio / Relative risk
Fig. 3 Associations of serum magnesium and magnesium intake with CAD, coronary heart disease and cardiovascular disease. The summary
results are from the current Mendelian randomisation study of genetically predicted serum magnesium levels in relation to CAD and a previous
meta-analysis of observational prospective studies of serum magnesium levels and dietary magnesium intake in relation to coronary heart disease
and cardiovascular disease. CAD coronary artery disease, CHD coronary heart disease, CI confidence interval, CVD cardiovascular disease, OR odds
ratio, RR relative risk
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observational studies [46], but there was little support for
a causal association between kidney function and coronary
heart disease in a recent MR analysis [47], suggesting that
the observed association between magnesium levels and
CAD in the present study is unlikely mediated by kidney
function. Further research is needed to better understand
the role of the genetic variants and their link to circulating
and intracellular magnesium levels.
Conclusions
This study based on genetics provides evidence that serum
magnesium levels are inversely associated with risk of
CAD. Randomised controlled trials elucidating whether
magnesium supplementation reduces the risk of CAD are
warranted. As magnesium supplementation is expected to
be most beneficial in individuals with an inadequate mag-
nesium status, such a trial may preferably involve a setting
with persons at higher risk of hypomagnesaemia.
Additional file
Additional file 1: Table S1. Association of genetically predicted
0.1-mmol/L increase in serum magnesium with coronary artery disease in
inverse-variance weighted and sensitivity analyses. Table S2. Genes
located in or near the loci for serum magnesium and their biological
roles. (DOCX 56 kb)
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